Clinical Trials Browser

Melanoma

NCT06305962 2026-02-19

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

BreastDermatologicGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07286318 2026-02-19

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

Phase EARLY_PHASE1 Not yet recruiting

20 enrolled

Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms, Keratosis, Actinic

NCT07144384 2026-02-13

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

40 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

22 enrolled

Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase EARLY_PHASE1 Active not recruiting

14 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT07389525 2026-02-05

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Phase EARLY_PHASE1 Not yet recruiting

80 enrolled

DermatologicGastrointestinalSarcoma

Gastrointestinal Neoplasms, Melanoma, Sarcoma, Urogenital Neoplasms

NCT05651828 2026-01-29

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

34 enrolled

Dermatologic

Skin Neoplasms

Clinical Trials

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma